Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Infection risk comparable between biologics, nonbiologics in children with psoriasis

04 Jun 2020

No substantial difference in infection risk is seen between biologics and nonbiologics among children with psoriasis, reveals a recent study. There is also no robust difference between systemic treatment and phototherapy.

“Independent of treatment, children with psoriasis had a higher risk of infection than those without psoriasis,” the authors said.

In this study, the authors estimated the 6-month risk of serious infections in children with psoriasis treated with biologics, systemic nonbiologics, and phototherapy. They used insurance claims data to identify children aged <18 years with psoriasis. The frequency of serious infections was compared in those initiating biologics, systemic nonbiologics, and phototherapy. Relative risks (RRs) were estimated before and after 1:1 propensity score matching.

A total of 57,323 children with psoriasis were identified. The 6-month infection risk was 4.2 per 1,000 patient-years in 722 biologic initiators, 5.1 in 988 systemic nonbiologic initiators, and 1.1 in 2,657 phototherapy initiators.

The RR was 0.67 (95 percent confidence interval [CI], 0.11–3.98) in biologics vs nonbiologics, 1.50 (95 percent, 0.25–8.95) in biologics vs phototherapy, and 5.00 (95 percent CI, 0.59–42.71) in nonbiologics vs phototherapy. Of note, the background risk of infection in children with psoriasis was 1 per 1,000, which was nearly double the risk compared with those without psoriasis (RR, 1.84, 95 percent CI, 1.15–1.97).

“Psoriasis is increasingly treated with systemic medications, yet their safety is not well characterized in children,” according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.